All SEC Filings

Date	Form	Description	PDF	XBRL	Pages
04/26/24	ARS	Annual report to security holders Documents ARS			65
04/26/24	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material			3
04/26/24	DEF 14A	Definitive proxy statements			33
04/09/24	SC 13D/A	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities			8
03/15/24	10-K	Annual report pursuant to Section 13 and 15(d) Documents EX-21.1 EX-23.1 EX-31.1 EX-31.2 EX-32.1 EX-32.2			82
03/14/24	SCHEDULE 13D/A	General Statement of Acquisition of Beneficial Ownership			4
02/15/24	8-K	Current report filing			3
02/15/24	25-NSE	Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities Documents EX-99.25			2
01/22/24	SC 13D	Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities			6
01/17/24	8-K	Current report filing			3

Our Research Partners

DairyExperts

We conducted in vivo pre-pilot and pilot studies in dairy cows with leading mastitis experts at a research firm based in Tulare County, California, showing positive results for combatting bovine mastitis, an inflammatory condition of the udder that impacts milk production.

Synthetic Genomics, Inc.

Commercial scaling and process improvements for algae cultivation were performed at SGI's Imperial Valley Facility, while the La Jolla facility mapped the genome of our proprietary algae strain in anticipation of a strain development program.

Harmon Consulting, Inc. (HCI)

We have worked with HCI on crucial technical aspects toward advancing our algae cultivation and processing technology. Their contributions span cultivation science, downstream processing, quality systems, and GRAS certification of the product. Their support in the development and training of the production staff will help to ensure ongoing project success.
www.harmonalgae.com

Contract Research Organizations

Our company works with leading CROs such as Charles River, a global contract research organization, and others to test, validate and analyze our products as we move toward market readiness.

Licensing Opportunities

Potential partners and licensees require proof that our nutritional and active components deliver on claims, therefore, we have engaged in a variety of validation, safety, interactions, and stability tests to prove such claims, and meet compliance regulations set forth by the FDA, USDA, EPA, and FTC.

We follow specific protocols and processes for all licensing packages, including our models for efficacy and compliance. Our intention is to expand our potential licensing opportunities based on new research and development data in the near future.